Benzo[<i>d</i>]imidazole-Naphthalen-Arylmethanone Regioisomers as CB₁ Ligands: Evaluation of Agonism via an Indirect Cytotoxicity-Based Approach.

ABSTRACT: CB₁ agonist compounds may be potential drug candidates for the treatment of gliomas, as they have been shown to inhibit tumor cell proliferation, induce apoptosis, and reduce angiogenesis in various preclinical models. Their ability to modulate the endocannabinoid system suggests a promising therapeutic approach for targeting glioma growth and progression. Herein, we report the design, synthesis, biological studies, and bioinformatics assays of novel benzo[d]imidazole-naphthalen-arylmethanone regioisomers with affinity for the CB₁ receptor, as well as propose an indirect methodology to evaluate their presumed CB₁ agonist activity. Compounds that showed a propensity for binding to the CB₁ receptor were regioisomers 4d, 5b,

SUBMITTER: Hwa Cho AY 

PROVIDER: S-EPMC12564498 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature